Phase 3 Trials: MDMA-Assisted Therapy for PTSD

On June 22, 2017, MAPS submitted to the U.S. Food and Drug Administration (FDA) an application for Breakthrough Therapy designation for our upcoming Phase 3 trials of MDMA-assisted psychotherapy for posttraumatic …

On June 13, as part of FDA’s Special Protocol Assessment process, MAPS submitted to FDA a revised Phase 3 protocol evaluating MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). The …

On May 11, 2017 MAPS and MPBC staff held a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the upcoming Phase 3 clinical trial of MDMA-assisted psychotherapy for PTSD. At the …